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Background: A disintegrin and metalloprotease 8 (ADAM8) has been reported to be associated with various
malignancies. However, no studies have examined ADAM8 association in colorectal cancer (CRC). The aim
of this study was to investigate the expression and function of ADAM8 in CRC.
Methods: Expression level of ADAM8 in CRC was evaluated by quantitative RT-PCR, western blot and
immunohistochemical staining analysis. The role of ADAM8 in colorectal carcinogenesis was evaluated by in vitro
assays. The correlations between ADAM8 status and clinicopathological features including survival were analyzed.
Results: ADAM8 was highly expressed in CRC tissues compared with adjacent normal tissues. Knockdown of ADAM8
in two CRC cell lines resulted in reduced cellular growth and proliferation, and increased apoptosis.
Immunohistochemistry analysis showed no significant correlations of ADAM8 protein expression with clinicopathologic
features. Survival analysis indicated that patients with ADAM8-positive tumors had worse 5-year overall survival (OS,
p = 0.037) and 5-year disease free survival (DFS, p = 0.014) compared with those with ADAM8-negative tumors.
Multivariate analysis indicated ADAM8 expression was an independent prognostic factor for both OS and DFS
(both p< 0.001). Subgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for
patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p< 0.05). The 5-year DFS in colon
cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups
was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p < 0.05).
Conclusions: Our results show that ADAM8 is overexpressed in CRC, promotes cell growth and correlates with
worse OS and DFS, and thus could serve as a biomarker for individual CRC patient therapy.
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Colorectal cancer (CRC) is the third most common cancer
and the fifth leading cause of cancer-related deaths, with
approximately 715,000 new cases and 70,000 deaths
annually in China. The survival of CRC patients is
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unless otherwise stated.characteristics, such as tumor location, differentiation grade
and TNM stages [1]. However, in practice, CRC patients
with the same pathological features may have different
prognosis. To discover new treatment options and more
precise assessment of this malignancy, some potential
therapy targets and candidate biomarkers have been re-
ported, such as adenomatous polyposis coli (APC) gene,
K-RAS gene, p53 gene and microsatellite instability (MSI)
[2]. Among these targets and candidate biomarkers, some
are used to justify whether adjuvant therapy is suitable for
individual CRC patients, including MSI and wild-type or
mutation of K-RAS and BRAF in certain exons [3-5].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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member of the human ADAM family, which contains
disintegrin and metalloprotease domains [6]. ADAM
proteins are involved in cell adhesion, cell migration,
cell fusion, membrane protein shedding and proteoly-
sis [7,8]. Aberrant expression of ADAM8 has been
identified in solid tumors, such as gliomas, lung cancer
[9], pancreatic cancer [10], renal cell carcinomas [11]
and prostate carcinomas [12]. ADAM8 overexpression
has been associated with poor prognosis in hepatocellular
carcinoma [13], breast cancer [14] and pancreatic adeno-
carcinoma [10], and might act as a potential therapeutic
target. Mechanistically, ADAM8 is involved in tumorigen-
esis by stimulating angiogenesis [14,15], increasing cellular
abilities of invasion and migration [10,14], and inhibiting
cancer cell apoptosis [16]. Previous studies showed that
ADAM9 [17], ADAM10 [18], ADAM17 [19], ADAM23
[20] and ADAM29 [21] were involved in colorectal
tumorigenesis and that ADAM8 was involved in lymph
node metastasis of gastric cancer. However, the possible
role of ADAM8 in CRC has not yet been evaluated. In
the present study, we report the identification of ADAM8
as a novel biomarker and a potential prognostic indicator,
and also provide evidence for its possible role in human
colorectal carcinogenesis.
Methods
Tissue samples, cell culture and cDNA preparation
Thirty CRC tissue samples sets (each containing tumor and
adjacent tissues) were obtained from the Sixth Affiliated
Hospital of Sun Yat-sen University. Adjacent normal tissues
were obtained at a distance of more than 5 cm from the
tumor margin and confirmed by a pathologist. Eight human
colorectal adenocarcinoma cell lines (HCT8, HT29,
SW620, SW480, DLD1, HCT116, LOVO and CACO2)
were purchased from the Culture Collection of Chinese
Academy of Science (Shanghai, China), and cultured in
RPMI 1640 supplemented with 10% fetal bovine serum
(Hyclone, USA) and 1% penicillin-streptomycin at 37°C in
a 5% CO2 incubator.
Total RNA from human CRC tissues cells was prepared
using Trizol reagent (Invitrogen, Carlsbad, CA). Reverse
transcription was performed using the ReverTra Ace
qPCR RT Kit (TOYOBO CO., Osaka, Japan) according to
the manufacturer’s instructions.
This study was approved by the institutional review
boards of Sun Yat-Sen University (Guangzhou, China),
and written informed consent was obtained from each
patient in this study.
Tissue microarray (TMA)
Three hundred and forty-two CRC samples were obtained
from the tumor bank of the Department of Pathology of
Sun Yat-Sen University (Guangzhou, China). The patientsunderwent initial surgical resection for CRC between
January 2000 and November 2006 and were followed
up until April 2010 to collect general information,
pathology reports, and information regarding the patients’
conditions after surgery. The samples were formalin-fixed
and paraffin-embedded.
TMAs were constructed using an automated TMA
instrument (ALPHELYS, Plaisir, France). After identi-
fying the hematoxylin and eosin (H&E)-stained slides
for optimal tumor tissue, two cylindrical core biopsies
(1 mm diameter) were punched from each formalin-fixed,
paraffin-embedded tissue block and arrayed in recipient
TMA blocks (2 × 3 cm) as previously described [22].
RNA interference (RNAi)
ADAM8 siRNA oligonucleotides (si-ADAM8-1 sense
5’-GGACAAGCUAUAUCAGAAAdTdT-3’ and antisense
3’-dTdTCCUGUUCGAUAUAGUCUUU-5’; and si-ADAM8-
2 sense 5’-GCACCUGCAUGACAACGUAdTdT-3’ and
antisense 3’-dTdTCGUGGACGUACUGUUGCAU-5’) and
siRNA control oligonucleotides were obtained from Ribo-
Bio Co. Ltd (Guangzhou, China). HT29 and SW480 cells
(1 × 105) were cultured in six-well plates until 50% conflu-
ence and transfected with 100 nM of the indicated siRNA
using LipofectamineImax (Invitrogen, CA, USA) according
to the manufacturer’s instructions. The effects of siRNA
silencing were analyzed after 48 h transfection. All ex-
periments were repeated three times.
Quantitative real-time polymerase chain reaction (qRT-PCR)
PCR was performed with each reaction containing 50 ng
of reverse-transcribed RNA and 1 μM 5’ and 3’ primers
in a 20 μL reaction. The primers used are listed in
Table 1. The reaction was performed on an ABI 7500
real-time PCR machine (Applied Biosystems, Foster City,
CA, USA) using the following conditions: 95°C for
2 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min.
Briefly, the relative RNA levels in each sample were
determined by performing standard curves. β-actin levels
were used for normalization.
Immunohistochemistry (IHC) staining
IHC was performed using the Polink-2 plus® Polymer
HRP Detection System (GBI, USA) according to the
manufacturer’s instructions. After deparaffinization in
xylene and rehydration through a graded alcohol series,
slides were transferred to sodium citrate buffer (Beijing
DingguoChangsheng Biotech Co. Ltd, AR-0511) for
15 min in the microware and left at room temperature
for 30 min. After blocking endogenous peroxidase,
slides were incubated with 10 μg/ml goat polyclonal
antibody specific to human ADAM8 (R&D Systems,
Inc., Minneapolis, MN) at 4°C overnight. Slides were
washed three times with phosphate-buffered saline (PBS)
Table 1 Primers used for qRT-PCR
Name Primer sequence forward Primer sequence reverse
ADAM8 5’-ACAATGCAGAGTTCCAGATGC-3’ 5’-GGACCACACGGAAGTTGAGTT-3’
β-actin 5’-CAATGAGCTGCGTGTGGCT-3’ 5’-TAGCACAGCCTGGATAGC AA-3’
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plus® supply) and Poly-HRP anti-Goat IgG (reagent 2,
Polink-2 plus® supply) for 30 min. Then the slides were
stained with DAB and counterstained with hematoxylin. A
negative control using antibody dilution as a substitute for
primary antibody was performed for each experiment.
ADAM8 staining was examined by two pathologists
blinded to clinicopathological data. Representative fields
were captured under low power (100 × magnification)
and high power (400 × magnification) by a Leica DMI
4000B inverted microscope (Leica Micro-systems, Wetzlar,
Germany). Disagreements were reevaluated until a con-
sensus was reached. IHC staining was analyzed using the
Image Pro-Plus (version 6.0, Media Cybernetics, Silver
Spring, USA) introduced by Xavier [23]. Briefly, the tumor
area was selected as the area of interest (AOI), and the
area sum and integrated optical density (IOD) of the AOI
were selected as the measurement parameters. ADAM8
expression index equaled the quotient between the IOD
and the total area of AOI. The mean expression index for
each duplicate was used for statistical analysis. Selection
of cutoff value was performed according to a previous
study [24]. The cutoff point was 9.79 based on the pa-
tient’s OS and DFS reaching significant difference. The
CRC tissues were classified based on ADAM8 density into
the negative group (less than or equal to 9.79) or positive
group (more than 9.79). The ADAM8 positive group in
cancer tissues and normal tissues was divided into three
subgroups of weak (9.79–64.5), moderate (64.5–111.2)
and strong (111.2–256.7) expression according to the
IHC scores based on OS and DFD reaching significant
difference.
Western blot
After 72 h transfection, HT29 and SW480 cells were
washed three times with PBS and lysed with RIPA buffer
(Dingguo, Beijing, China) supplemented with phenyl-
methanesulfonyl fluoride (PMSF, Dingguo, Beijing, China).
ADAM8 protein levels were determined using two-color
fluorescent western blotting on the Odyssey infrared im-
aging system (LI-COR, Nebraska, USA). In brief, protein
samples were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to a polyvinylidene fluoride (PVDF) membrane
(Pall, New York, USA). Membranes were then blocked
with 5% skim milk for 1 h. Proteins were detected
using mouse monoclonal antibodies specific to human
ADAM8 (diluted 1:250, Abcam, UK, ab89127) and β-actin(diluted 1:10,000, Protein Tech, Chicago, USA). After
incubating with primary antibodies overnight at 4°C
and species-appropriate fluorescently conjugated sec-
ondary antibodies for 1 h at room temperature, the
blots were observed using the Odyssey infrared im-
aging system. Secondary antibodies were purchased
from Santa Cruz Biotechnology (CA, USA) unless other-
wise indicated.
Cell viability and cell proliferation assay
HT29 and SW480 cells were seeded in 96-well plates at
a density of 1 × 104 cells/well. Cells were transfected
with ADAM8 siRNA and cell viability was determined 0,
1, 2, 3, and 4 days later using the CellTiter 96 Aqueous
One Solution Cell Proliferation Assay kit (Promega,
Madison, WI) according to the manufacturer’s protocol.
After 72 h of transfection with ADAM8 siRNA, cell prolif-
eration assay was performed using an EDU (5-ethynyl-2’-
deoxyuridine) Cell Proliferation Kit (Invitrogen, Camarillo,
CA) according to the manufacturer’s instructions. Data
are presented as mean ± SD for three independent ex-
periments compared with the control group, and each
experiment was performed in triplicate.
Cell apoptosis assay
HT29 and SW480 cells transfected with ADAM8 siRNA
were seeded in 12-well plates at a density of 1 × 104
viable cells/well. After 72 h culture, the cells were fixed
in 70% ethanol and stained with 50 mg/ml propidium
iodide (BD Pharmingen, San Jose, CA, USA), then sorted
by FACSCalibur (BD Biosciences, Franklin Lakes, NJ,
USA). Cell cycle profiles were analyzed by ModFit
3.0 software (Verity Software House, Topsham, ME,
USA). Apoptosis was determined by dual staining with
Annexin V:FITC and propidium iodide (Invitrogen).
The Annexin V-positive cells were counted as apoptotic
cells.
Statistical analyses
SPSS 16.0 for Windows (SPSS, Inc., Chicago, IL) was
used for statistical analyses. Continuous variables were
expressed as mean ± SD and analyzed by t-test. The
Chi-square test was used to show differences of cat-
egorical variables. Survival analysis was performed
using the Kaplan-Meier method and compared using
the log-rank test. P< 0.05 was considered statistically
significant.
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Expression status of ADAM8 gene in human CRC tissues
and cell lines
We evaluated the expression of ADAM8 protein and
mRNA levels in 30 pairs of fresh-frozen CRC tissues
and adjacent normal tissues by IHC and qRT-PCR. IHCFigure 1 ADAM8 expression status in CRC tumor and normal
tissues. A, Expression of ADAM8 in tumor and normal colon tissues
detected by IHC. Representative images of IHC staining of colon
tissues with anti-ADAM8 antibody on tumor and normal tissues
(100× for left panel and 400× for right panel). B, Mean expression
levels of ADAM8 mRNA in tumor tissues were significantly higher
than that observed in normal tissues (p = 0.0018). The expression of
ADAM8 mRNA was normalized to β-actin mRNA, which served as a
control for the input cDNA.results showed that specific ADAM8 staining was mainly
detected in the cytoplasm and membrane of noncancerous
and malignant epithelial cells. IHC staining indicated more
CRC tissues with positive ADAM8 expression than in
corresponding adjacent normal tissues (81.0% vs. 33.3%,
respectively; p< 0.0001) (Figure 1A, Table 2). Among the
24 CRC patients with ADAM8 positive tumor tissues,
high and moderate expression of ADAM8 was detected
in 20 cases and weak expression in 4 cases. Among paired
adjacent normal tissues, weak expression of ADAM8 pro-
tein was found in 10 cases, while no cases showed high or
moderate expression. The mRNA expression levels of
ADAM8 were evaluated by qRT-PCR and representative
data are shown in Figures 1B and 1C. The mean expres-
sion levels of ADAM8 mRNA were significantly higher in
tumor tissues compared with those in adjacent normal tis-
sues (2.74 ± 0.17 vs. 1.04 ± 0.09, respectively; p = 0.0018).
The expression of ADAM8 mRNA was normalized to
β-actin mRNA, which served as a control for the input
cDNA.
Expression levels of ADAM8 mRNA and protein were
also measured in eight CRC cell lines (Figure 2A). The
expression level of ADAM8 protein was consistent with
mRNA expression level in HCT8, HT29, SW620, SW480,
HCT 116 and CACO2 cell lines, but not in DLD1 and
LOVO cell lines. Based on these results, we selected
HT29 and SW480 cell lines for further analysis. To ex-
plore the potential effect of ADAM8 on CRC carcino-
genesis, two ADAM8 siRNA oligonucleotides were
generated to knockdown ADAM8 expression in HT29 and
SW480 cells. Transfection with si-ADAM8-1 decreased
ADAM8 mRNA expression levels by 84.3% in HT29 cells
(p < 0.001) and by 82.7% in SW480 cells (p < 0.001) com-
pared with control siRNA. Transfection with si-ADAM8-2
decreased ADAM8 mRNA levels by 82.7% in HT29
cells (p < 0.001) and by 78.8% in SW480 cells (p < 0.001)
(Figure 2B and C, top panel). Western blot analysis con-
firmed the qRT-PCR results (Figure 2B and C, bottom
panel).
Knockdown of ADAM8 influences proliferation and
apoptosis of CRC cells
Cell proliferation assays revealed that si-ADAM8-1-
mediated decreased expression of ADAM8 significantly
inhibited cell proliferation in HT29 cells (down to 30.5%;
p < 0.01), and si-ADAM8-2 transfection also inhibitedTable 2 Comparison of ADAM8 protein level in normal
and tumor tissues by IHC (n = 42)
Tissue ADAM8 expression χ2 p value
Negative Positive
Normal 20(66.7%) 10(33.3%) 13.3 <0.0001
Tumor 6(19.0%) 24(81.0%)
Figure 2 Expression of ADAM8 in CRC cell lines. A, Expression of
ADAM8 mRNA (top) and protein level (bottom) in HCT8, HT29,
SW620, SW480, DLD1, HCT116, LOVO and CACO2 cell lines. B, C,
Significantly decreased expression of ADAM8 mRNA (top) and
protein levels (bottom) in ADAM8 siRNA-transfected HT29 cells (B)
and SW480 cells (C) compared with the control group (p < 0.001).
The expression of ADAM8 mRNA was normalized to β-actin mRNA,
which served as the control. Data are expressed as the mean ± standard
deviation (SD).
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Similar results were observed in SW480 cells transfected
with si-ADAM8-1 (down to 45.6%; p < 0.001) and si-
ADAM8-2 (down to 45.2%; p < 0.001) (Figure 3A). Cell
viability assay demonstrated that knockdown of ADAM8
significantly inhibited cell growth in both SW480
(Figure 3B) and HT29 cells (Figure 3C). Cell cycle
and apoptosis assay showed that the percentage of cell
apoptosis in siADAM8-transfected HT29 and SW480
cells was significantly higher than that in control cells
(Figure 3D). Together these results suggest that ADAM8
is involved in CRC carcinogenesis by accelerating prolifer-
ation/growth and inducing apoptosis of CRC cells.
Correlation of ADAM8 expression with clinicopathological
characteristics and long-term survival of CRC
The association between ADAM8 expression and clinico-
pathological characteristics was assessed in 342 primary
CRC patients. IHC was used to detect ADAM8 protein
expression status, and tissues were scored as positive or
negative as described in Materials and Methods. Among
342 CRC patients, ADAM8 was positive in 261 cases
(76.3%) and negative in 81 cases (23.7%). However, no sig-
nificant correlations were found between ADAM8 expres-
sion status and clinicopathological indicators (Table 3).
The correlation of ADAM8 protein expression and post-
operative survival was also evaluated. Five-year overall
survival (OS) and disease-free survival (DFS) for all pa-
tients were 73% and 70%, respectively. The 5-year OS for
patients with ADAM8 positive tumors was significantly
poorer than those with ADAM8 negative tumors (70% vs.
81%, respectively; p = 0.037) (Figure 4A). Similar results
were found for the 5-year DFS of CRC patients with
positive and negative ADAM8 tumors (53% vs. 80%,
respectively; p = 0.014) (Figure 4B).
Regarding 5-year OS, univariate analysis indicated that
T stage, N stage, M stage, TNM stage, differentiation
grade, preoperative CEA and CA19-9 levels, and ADAM8
protein expression status were found to be prognostic
factors (Table 4). However, multivariate analysis demon-
strated that TNM stage, preoperative CEA levels and
ADAM8 protein expression status (HR = 1.943; 95% CI:
1.089–3.465, p = 0.024) were independent prognostic
indicators (Table 4). Further analysis for OS in each
Figure 3 ADAM8 influences proliferation and apoptosis of CRC cells. ADAM8 siRNA-mediated reduction of ADAM8 significantly inhibited
proliferation (A) and growth (B and C) of HT29 and SW480 cells compared with the control group. D, Knockdown of ADAM8 significantly
induced cell apoptosis in HT29 and SW480 cells compared with controls.
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Table 3 Association between ADAM8 expression in CRC and clinicopathologic characteristics (n = 342)
Indicator ADAM8 expression χ2 p





≤65 yrs 51(63.0%) 150(57.5%)




T stage 0.465 0.495
T1-T2 16(19.8%) 43(16.5%)
T3- T4 65(80.2%) 218(83.5%)
N stage 1.675 0.196
N0 54(66.7%) 153(58.7%)
N1- N2 27(33.3%) 108(41.3%)
M stage 0.256 0.613
M0 68(84.0%) 225(86.2%)
M1 13(16.0%) 36(13.8%)









Histological type 1.209 0.272
Adenocarcinoma 72(88.9%) 219(83.9%)
Mucinous/Signet-ring adenocarcinoma 9(11.1%) 42(16.1%)
CA19-9 (ug/L) 3.582 0.058
≤60 67(82.2%) 236(90.4%)
>60 14(17.8%) 25(9.6%)
CEA (ug/L) 0.225 0.635
≤5 52(64.2%) 175(67.0%)
>5 29(35.8%) 86(33.0%)
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tumors have poorer 5-year OS than those with negative
ADAM8 in colon cancer (p = 0.006) (Figure 5A), T3/T4
stage (p = 0.023) (Figure 5B) and N0 stage (p = 0.032)
(Figure 5C) subgroups compared with rectal cancer, T1/T2
stage and N1-2 stage patients. No significant correlation
was found with other subgroups.Regarding 5-year DFS, N stage, differentiation grade,
TNM stage, preoperative CEA and CA19-9 levels, and
ADAM8 protein expression status were found to be
prognostic factors by univariate analysis (Table 5).
However, TNM stage, preoperative CEA levels and
ADAM8 protein expression status (HR = 2.108; 95%
CI: 1.922–3.480, p = 0.025) were independent prognostic
Figure 4 Survival of CRC patients according to the expression status of ADAM8 protein. A, CRC patients with positive ADAM8 had
poorer OS than those with negative ADAM8 (p = 0.037). B, CRC patients with positive ADAM8 had poorer DFS than those with negative
ADAM8 (p = 0.014).
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http://www.biomedcentral.com/1471-2407/14/568indicators by multivariate analysis (Table 5). Further ana-
lysis for DFS in subgroups showed that patients with
positive ADAM8 expression had poorer 5-year DFS
than those with negative ADAM8 expression in colon
cancer (p = 0.001) (Figure 6A), T3/T4 stage (p = 0.009)
(Figure 6B), N0 stage (p = 0.010) (Figure 6C), TNM II
stage (p = 0.045) (Figure 6D), adenocarcinoma (p =
0.027) (Figure 6E), moderate differentiation (p = 0.043)
(Figure 6F) and male CRC patients (p = 0.030) (Figure 6G)
subgroups. No significant correlations were found with
other indicators.Discussion
A member of the ADAM family, ADAM8 has been de-
tected in many cell types and various types of cancer
[12,25-30]. However, no study of ADAM8 expression
in CRC patients has been performed. In the present
study, expression of both protein and mRNA levels of
ADAM8 in 30 CRC patients were significantly higher in
cancerous tissues than corresponding adjacent normal
tissues, suggesting its importance in CRC carcinogenesis.
IHC analysis of 342 CRC patients identified 261 (76.3%)
cases with positive ADAM8 expression and 81 (23.7%)
Table 4 Univariate and multivariate analyses of the prognostic factors for 5-year OS of CRC patients (n = 342)
Indicator Univariate analysis Multivariate analysis
5-year OS p value HR 95% CI p value
T stage
T1-T2 79% 0.009 NS
T3-T4 64%
N stage
N0 78% <0.0001 NS
N1-N2 61%
M stage
M0 73% <0.0001 NS
M1 23%
Differentiation grade




I 86% <0.0001 1 Reference <0.0001
II 78% 1.016 0.411-2.511
III 69% 1.674 0.686-4.083
IV 22% 9.685 3.773-24.862
CEA(ug/L)
≤5 80% <0.0001 1 Reference 0.006





Negative 81% 0.037 1 Reference 0.024
Positive 67% 1.943 1.089-3.465
CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; NS, not significant.
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is upregulated in human CRC. To explore the potential
role of ADAM8 in CRC carcinogenesis, cell proliferation
and apoptosis assay were used to assess the influence
of ADAM8 on cell growth. Our findings showed that
siRNA-mediated downregulation of ADAM8 in CRC
cells significantly suppressed cell proliferation and in-
duced cell apoptosis, which is in agreement with previ-
ous reports [13,16]. These data strongly suggest that
ADAM8 is involved in CRC carcinogenesis and regu-
lates cell growth by accelerating cell proliferation and
inhibiting cell apoptosis. Although previous studies have
shown that ADAM8 increases invasion and migration
abilities of tumor cells [14,15,21], we did not find a signifi-
cant decrease of invasion and migration in ADAM8
siRNA-transfected cells compared with control cells (data
not shown).In the present study, we explored the relationship be-
tween ADAM8 expression status and clinicopathological
features in CRC. Although previous studies reported that
ADAM8 expression correlates significantly with tumor
size, histological differentiation, regional and distant
metastasis, tumor stages in several cancers progression
[12,13,29,31], we did not find any significant correlations
between ADAM8 expression status and any clinicopatho-
logical feature in CRC.
In the present study, patients with ADAM8 positive
tumors have poorer 5-year OS and DFS than those
with ADAM8 negative tumors. Multivariate analysis
revealed that ADAM8 positive expression could act as
an important factor for unfavorable prognosis in both
OS and DFS for CRC patients independent of some
conventional indicators, which is in agreement with
published papers [25,29,30]. Further analysis of survival
Figure 5 Five-year OS of patients with positive ADAM8 versus
negative ADAM8 tumors in (A) colon cancer (p = 0.006), (B)
T3/4 depth of invasion (p = 0.023) and (C) N0 stage (p = 0.032).
Table 5 Univariate and multivariate analyses of the
prognostic factors for 5-year DFS of CRC patients (n = 292)
Indicator Univariate analysis Multivariate analysis
5-year DFS p value HR 95% CI p value
N stage
N0 68% 0.031 NS
N1-N2 59%
Grade




I 85% 0.017 1 Reference 0.027
II 72% 2.445 0.958-6.236
III 61% 2.482 0.954-6.457
CEA(ug/L)
≤5 75% <0.0001 1 Reference 0.001
>5 52% 2.052 1.342-3.145
CA19-9 (ug/L)
≤60 69% 0.016 NS
>60 55%
ADAM8 protein
Negative 81% 0.014 1 Reference 0.025
Positive 67% 2.108 1.922-3.480
CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; NS, not significant.
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nostic factor for colon cancer but not for rectal cancer,
indicating that ADAM8 may not function as a bio-
marker for rectal cancer. Meanwhile, positive ADAM8
was an adverse indicator for both OS and DFS in T3/T4
depth of invasion and N0 stage, and only for DFS in
adenocarcinoma, moderately differentiated tumors and
male patients. Based on these results, ADAM8 can be
considered as a novel prognostic marker for CRC and
may serve as a target for individual therapy for certain
CRC patients.
Although we explored the expression status, potential
roles and clinical implications of ADAM8 in CRC, the
underlying mechanism by which ADAM8 influences
tumor cell growth and postoperative survival of CRC
patients was not investigated in this study. Furthermore,
although high expression of ADAM8 induces tumor cell
resistance to chemotherapy [16], we were unable to assess
the role of post-operative adjuvant chemotherapy with re-
gard to DFS and OS in context of ADAM8 expression in
univariate and multivariate analyses due to the shortage of
post-operative adjuvant chemotherapy data for 342 CRC
patients in this study. More studies investigating these
questions should be performed in the future.
Figure 6 Five-year DFS of patients with positive ADAM8 versus negative ADAM8 tumors in (A) colon cancer (p = 0.001), (B) T3/4 stage
(p = 0.009), (C) N0 stage (p = 0.032), (D) TNM II stage (p = 0.045), (E) adenocarcinoma (p = 0.027), (F) moderate differentiation (p = 0.043)
and (G) male CRC patients (p = 0.030).
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In summary, our results show that ADAM8 is over-
expressed in CRC tissues, promoting cancer cell pro-
liferation, inducing cell apoptosis and correlating with
worse OS and DFS. Furthermore, ADAM8 may be
considered as a novel prognostic marker for CRC andcould function as a target of individual therapy for certain
CRC patients.Abbreviations
ADAM8: A disintegrin and metalloprotease 8; CRC: Colorectal cancer;
OS: Overall survival; DFS: Disease-free survival; qRT-PCR: Quantitative RT-PCR.
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